The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Improved survival in women with BRCA‐associated ovarian carcinoma
Open accessAbstract
BACKGROUND: The objective of this study was to determine the clinical characteristics, treatment response, and frequency of p53 overexpression in Ashkenazi Jewish women with hereditary ovarian carcinoma. METHODS: Seventy‐one Jewish women with epithelial ovarian carcinoma (EOC) were tested for the three BRCA founder mutations using single‐strand conformation polymorphism analysis, heteroduplex analysis, and protein truncation testing. Clinical and histopathologic data were reviewed retrospectively. In vitro chemoresistance was analyzed in 32 patients. Mutations of p53 were studied using immunohistochemical detection of p53 overexpression. RESULTS: Thirty‐four of 71 Jewish patients with EOC (48%) had germline BRCA mutations (BRCA heterozygotes), including 22 BRCA1 mutations and 12 BRCA2 mutations. BRCA heterozygotes were younger compared with Jewish patients who had EOC without mutations (sporadic carcinoma; 50 years vs. 59 years, respectively; P = 0.01). BRCA1 heterozygotes were younger compared with BRCA2 heterozygotes (48 years vs. 57 years, respectively; P = 0.01). Histopathologic tumor features were similar; however, tumors with low malignant potential were seen only in women with sporadic carcinoma. Both groups had equivalent rates of surgical cytoreduction and similar median follow‐up (72 months). BRCA heterozygotes had higher response rates to primary therapy compared with patients who had sporadic disease (P = 0.01). In vitro chemoresistance predicted tumor response to platinum chemotherapy correctly in BRCA heterozygotes (P = 0.0096). BRCA heterozygotes with advance‐stage disease had improved survival compared with patients who had advanced stage sporadic carcinoma (91 months vs. 54 months, respectively; P = 0.046) and had a longer disease free interval (49 months vs. 19 months, respectively; P = 0.16). p53 overexpression was common in BRCA heterozygotes (80%). CONCLUSIONS: BRCA1 heterozygotes developed EOC at a younger age compared with BRCA2 heterozygotes and women who had sporadic ovarian carcinoma. BRCA heterozygotes had a better response to platinum chemotherapy compared with women who had sporadic disease, which may have contributed to their improved prognosis. Cancer 2003;97:2187–95. © 2003 American Cancer Society. DOI 10.1002/cncr.11310
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Self-citationBristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Gene-Expression Profiles in Hereditary Breast Cancer
Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Raffeld, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440801 · Cited by 1,733
Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells
Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81847-4 · Cited by 1,459
Cortez, D., Wang, Y., Qin, J., & Elledge, S. J. (1999) · Science · doi:10.1126/science.286.5442.1162 · Cited by 1,020
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318787 · Cited by 986
Self-citationPrevalence of BRCA1 and BRCA2 Gene Mutations in Patients With Early-Onset Breast Cancer
Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., Easton, D. F., Evans, C., Deacon, J., & Stratton, M. R. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.11.943 · Cited by 873
Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X.-W., Harris, C. C., Ried, T., & Deng, C.-X. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80466-9 · Cited by 819
Cited by
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Self-citationDNA interstrand crosslink repair and cancer
Deans, A. J., & West, S. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3088 · Cited by 1,023
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V. D., Cox, B. F., DeWeese, T. L., Dillehay, L. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3039 · Cited by 773
Recent progress in the diagnosis and treatment of ovarian cancer
Jelovac, D., & Armstrong, D. K. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20113 · Cited by 765
Hereditary Cancer Predisposition Syndromes
Garber, J. E., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.042 · Cited by 697
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J., Arango, H., LaPolla, J., Hoffman, M., Martino, M. A., Wakeley, K., et al. (2005) · Cancer · doi:10.1002/cncr.21536 · Cited by 691
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680
Self-citationTelomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Birkbak, N. J., Wang, Z. C., Kim, J.-Y., Eklund, A. C., Li, Q., Tian, R., Bowman-Colin, C., Li, Y., Greene-Colozzi, A., Iglehart, J. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0206 · Cited by 661
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Yang, D., Khan, S., Sun, Y., Hess, K., Shmulevich, I., Sood, A. K., & Zhang, W. (2011) · JAMA · doi:10.1001/jama.2011.1456 · Cited by 599
Kauff, N. D., Domchek, S. M., Friebel, T. M., Robson, M. E., Lee, J., Garber, J. E., Isaacs, C., Evans, D. G., Lynch, H., Eeles, R. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9626 · Cited by 589
Norquist, B., Wurz, K. A., Pennil, C. C., Garcia, R., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 577
Self-citationOncogenes and Tumor Suppressor Genes
Lee, E. Y. H. P., & Muller, W. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003236 · Cited by 508
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 483
Self-citationTan, D. S. P., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., Ardern-Jones, A., Norman, A., Kaye, S. B., & Gore, M. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1703 · Cited by 469
The Fanconi Anemia/BRCA pathway: new faces in the crowd
Kennedy, R. D., & D'Andrea, A. D. (2005) · Genes & Development · doi:10.1101/gad.1370505 · Cited by 467
Early Events in the Pathogenesis of Epithelial Ovarian Cancer
Landen, C. N., Birrer, M. J., & Sood, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9970 · Cited by 462
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
Golan, T., Kanji, Z. S., Epelbaum, R., Devaud, N., Dagan, E., Holter, S., Aderka, D., Paluch-Shimon, S., Kaufman, B., Gershoni-Baruch, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.418 · Cited by 436
“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
Davis, A., Tinker, A. V., & Friedlander, M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.038 · Cited by 433
The Role of BRCA1 in the Cellular Response to Chemotherapy
Kennedy, R. D., Quinn, J. E., Mullan, P. B., Johnston, P. G., & Harkin, D. P. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh312 · Cited by 430
Zhang, S., Royer, R., Li, S., McLaughlin, J. R., Rosen, B., Risch, H. A., Fan, I., Bradley, L., Shaw, P. A., & Narod, S. A. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.01.020 · Cited by 423
Self-citationHennessy, B. T. J., Timms, K. M., Carey, M. S., Gutin, A., Meyer, L. A., Flake, D. D., Abkevich, V., Potter, J., Pruss, D., Glenn, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2997 · Cited by 374
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., Kladny, J., Gorski, B., Lubinski, J., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0128-9 · Cited by 340
Self-citationHereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
Petrucelli, N., Daly, M. B., & Feldman, G. L. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181d38f2f · Cited by 339
Chetrit, A., Hirsh-Yechezkel, G., Ben-David, Y., Lubin, F., Friedman, E., & Sadetzki, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6905 · Cited by 323
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Press, J. Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S. E., Blood, K. A., Smith, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-17 · Cited by 287
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
Kennedy, R. D., & D'Andrea, A. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4171 · Cited by 286
Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging
Plevritis, S. K., Kurian, A. W., Sigal, B. M., Daniel, B. L., Ikeda, D. M., Stockdale, F. E., & Garber, A. M. (2006) · JAMA · doi:10.1001/jama.295.20.2374 · Cited by 260
Gene Expression Signature With Independent Prognostic Significance in Epithelial Ovarian Cancer
Spentzos, D., Levine, D. A., Ramoni, M. F., Joseph, M., Gu, X., Boyd, J., Libermann, T. A., & Cannistra, S. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.070 · Cited by 255
Kang, J., D’Andrea, A. D., & Kozono, D. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs177 · Cited by 167
Hereditary breast cancer: From molecular pathology to tailored therapies
Tan, D. S. P., Marchiò, C., & Reis-Filho, J. S. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.057950 · Cited by 60
BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer
Pothuri, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt307 · Cited by 50
Determinants of quality of life in ovarian cancer survivors: a pilot study
Teng, F. F., Kalloger, S. E., Brotto, L., & McAlpine, J. N. (2014) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30513-2 · Cited by 42
Szabova, L., Bupp, S., Kamal, M., Householder, D. B., Hernandez, L., Schlomer, J. J., Baran, M. L., Yi, M., Stephens, R. M., Annunziata, C. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095649 · Cited by 25
“Brca1 genotype-specific responses to platinum drugs as well as olaparib have also been documented in patients [34–37], therefore the orthotopic model is a useful tool for examining these differential responses and predicting potential outcomes.”
BackgroundResultLu, J., Wu, D., Li, C., Zhou, M., & Hao, D. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1191-9 · Cited by 24
Metadata
- Authors
- Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-04-17
- Volume
- 97
- Issue
- 9
- Pages
- 2187-2195
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2059000312
- Cited by
- 433
- References
- 49
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.